Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 5NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Genitourinary 2Gastrointestinal 2Other hematologic neoplasm 1Gynecologic 1

Conditions

Leukemia, Hairy Cell 1

Interventions

Cytarabine 117Cyclophosphamide 88Etoposide 59Daunorubicin 58fludarabine phosphate 50Specimen Handling 49Methotrexate 49Filgrastim 48Vincristine 47Biopsy 47Rituximab 43Radiotherapy 34Dexamethasone 34Peripheral Blood Stem Cell Transplantation 32Doxorubicin 29Mitoxantrone 27Idarubicin 27Busulfan 27Azacitidine 27Prednisone 26Mercaptopurine 26Leucovorin 26fludarabine 25Decitabine 24Asparaginase 24venetoclax 23merphos 22Bortezomib 22Cyclosporine 20alvocidib 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × High-Energy Shock Waves × Other hematologic neoplasm × Clear all
NCT01841723 2026-05-13

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
44 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡